Table of contents
Chargebacks account for more than 30% of net sales in pharma—and with up to 75% of claims containing discrepancies, they remain one of the industry’s most error-prone processes. At FutureLink Boston 2025, Lucy Deus, Senior Vice President of Supply Network Products at TraceLink, unpacked the hidden costs behind chargeback complexity and laid out a clear path forward.
In this session, Deus explains how to eliminate reconciliation errors by leveraging EPCIS, serialized product data, and digital transaction exchange. From ASN and PO alignment to the strategic use of serialization data, she shares how TraceLink MINT helps manufacturers and wholesalers automate chargeback workflows and improve financial accuracy.
- How misaligned master data, outdated contract terms, and duplicate claims create chargeback risk
- Why serialization and EPCIS data are essential for end-to-end traceability and reimbursement verification
- How TraceLink MINT enables real-time reconciliation through seamless transaction exchange across partners
Watch now to see how digitalization and intelligent orchestration are transforming chargeback management in pharma.
